Newsroom | 4413 results

LOS ANGELES--(BUSINESS WIRE)--Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the appointment of Maykin Ho, Ph.D., to its board of directors, and the promotions of Nathan Wheeler to Chief Operating Officer and Lisa Sherman to Vice President, Head of Clinical Operations. “We are pleased to welcome Maykin to Pelage’s board as an independent director and to announce key leadership promotions within our organization,” said Daniel Gil, Ph.D., Chi...

SAN FRANCISCO--(BUSINESS WIRE)--Animate Biosciences Reports Preclinical Data Showing Reduced Cardiac Scarring and Nearly Doubled Heart Function After Heart Attack....

CAMBRIDGE, England--(BUSINESS WIRE)--Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to substantially lower the price per vial of its ioCells™ portfolio. This initiative is further strengthened by the launch of bit.bio’s second dedicated distribution hub, expanding on its existing US hub, and now enabling EU-based researchers to benefit from reduced lead times, lower logistical costs, and less administr...

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 3...

SOUTH SAN FRANCISCO, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and the University of Wisconsin (UW) School of Medicine and Public Health today announced an expansion of their partnership to support clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy for pediatric and adult solid tumors. The collaboration builds on the initial partnership announced in Ap...

TAMPA, Fla. & SEOUL, South Korea--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease. TED‑A9 represents S.Biomedics’ ambition to deliver a new class of regenerative medicine for patients with Parkinson’s disease. The program reflects years...

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced that the FDA's Center for Drug Evaluation and Research (CDER) has accepted the company’s letter of intent (LOI) into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Program for its Human iPSC-Cardiomyocyte MEA Assay for Prediction of Clinical Cardiovascular Repolarization Risk. The submission represents the first stem cell-derived, functional cardiac safety assay accepted into the ISTAND program. The ISTAND progr...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking plac...

CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery’s™ rapid multiplex membrane protein screening with leadXpro’s AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis.  MEDIPOST’s investigational therapy is an umbilical cord...